A RESOLUTION

- 1
- Designating the week of May 20 through 26, 2013, as "Arteriovenous Malformation Awareness Week" in Pennsylvania.
- WHEREAS, Arteriovenous malformation (AVM) is a rare, 3
- nonhereditary congenital defect characterized by tangled 4
- arteries and veins that are not connected by capillaries; and 5
- WHEREAS, Blood circulating through the abnormal vessels flows 6
- rapidly under high pressure, preventing nutrient-rich arterial
- blood from reaching tissue; and 8
- WHEREAS, According to the National Institute of Neurological 9
- Disorders and Stroke (NINDS), which is part of the National 10
- Institutes of Health (NIH), approximately 300,000 Americans have 11
- 12 AVMs; and
- WHEREAS, NINDS reports that each year about 1% of persons 13
- with AVMs will die as a result of the AVMs; and 14
- WHEREAS, While occurring in fairly equal rates in men and 15
- women of all racial or ethnic backgrounds, AVMs are still more 16
- 17 common among males; and

- 1 WHEREAS, Because most people with AVMs do not know that they
- 2 have them, it is imperative that the public become better
- 3 educated; and
- 4 WHEREAS, According to the International RadioSurgery
- 5 Association, AVMs are the leading cause of stroke in young
- 6 people between 10 and 30 years of age; and
- 7 WHEREAS, According to NINDS, most people with AVMs experience
- 8 few, if any, significant symptoms, and malformations tend to be
- 9 discovered only incidentally, usually during autopsy or
- 10 treatment for an unrelated disorder; and
- 11 WHEREAS, Twelve percent of the affected population, or 36,000
- 12 of the estimated 300,000 Americans with AVMs, experience
- 13 symptoms that vary greatly in severity, with a small fraction of
- 14 this group having debilitating or even life-threatening
- 15 symptoms; and
- 16 WHEREAS, AVMs can cause a wide array of neurological symptoms
- 17 such as muscle weakness, partial paralysis, loss of
- 18 coordination, difficulties performing tasks which require
- 19 planning, dizziness, visual disturbances, inability to control
- 20 eye movement and optic disk swelling; and
- 21 WHEREAS, AVMs can cause problems in using and understanding
- 22 language, abnormal sensations such as numbness, tingling or
- 23 spontaneous pain, memory loss, mental confusion, hallucinations
- 24 or dementia; and
- 25 WHEREAS, Treatment depends on the type and location of the
- 26 AVM and the condition of the patient; and
- 27 WHEREAS, Although AVM symptoms are often alleviated with
- 28 medication, the most effective treatments include surgery,
- 29 radiation therapy and embolization; and
- 30 WHEREAS, Researchers have difficulty classifying the

- 1 different kinds of AVMs and developing new treatments; and
- WHEREAS, NINDS, which is recognized as a leading sponsor of
- 3 AVM research, conducts research studies in partnership with
- 4 medical institutions such as Columbia University Medical Center;
- 5 and
- 6 WHEREAS, The NINDS-Columbia partnership created the
- 7 Arteriovenous Study Group, which has been conducting long-term
- 8 research on the natural course of AVMs in patients and
- 9 improvements in AVM surgeries; and
- 10 WHEREAS, As research efforts progress, the public is
- 11 encouraged to learn all they can about AVM, share it with their
- 12 families and friends and provide aid and comfort for traumatized
- 13 loved ones who have been touched by this disorder; therefore be
- 14 it
- 15 RESOLVED, That the House of Representatives designate the
- 16 week of May 20 through 26, 2013, as "Arteriovenous Malformation
- 17 Awareness Week" in Pennsylvania.